177 related articles for article (PubMed ID: 36305753)
1. Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.
Wang H; Tran TT; Duong KT; Nguyen T; Le UM
Mol Pharm; 2022 Dec; 19(12):4487-4505. PubMed ID: 36305753
[TBL] [Abstract][Full Text] [Related]
2. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
3. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
[TBL] [Abstract][Full Text] [Related]
4. Melanoma: An update on systemic therapies.
Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
[TBL] [Abstract][Full Text] [Related]
5. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
7. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
8. Major Changes in Systemic Therapy for Advanced Melanoma.
Thompson JA
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):638-40. PubMed ID: 27226502
[TBL] [Abstract][Full Text] [Related]
9. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
10. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
11. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Gil-Rojas Y; Lasalvia P; Hernández F; Castañeda-Cardona C; Castrillón-Correa J; Herrera D; Rosselli D
Value Health Reg Issues; 2021 Dec; 26():182-190. PubMed ID: 34673349
[TBL] [Abstract][Full Text] [Related]
13. Lifileucel (Amtagvi): A cellular therapy for melanoma.
Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651
[No Abstract] [Full Text] [Related]
14. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
Front Oncol; 2022; 12():865656. PubMed ID: 35530323
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Melanoma: Recent Advances and Promising New Therapies.
Saraceni MM; Khushalani NI; Jarkowski A
J Pharm Pract; 2015 Apr; 28(2):193-203. PubMed ID: 24674910
[TBL] [Abstract][Full Text] [Related]
17. Current systemic therapies for melanoma.
Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
[TBL] [Abstract][Full Text] [Related]
18. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
20. The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
John L; Cowey CL
Dermatol Ther (Heidelb); 2015 Sep; 5(3):151-69. PubMed ID: 26387031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
